3DBiopsy, Inc. is a medical device company that is developing a comprehensive System ultimately intended to aid in the diagnosis and treatment planning of prostate cancer—the most commonly diagnosed significant male cancer and second leading cause of cancer deaths. Created by prostate cancer specialists, the 3DBiopsy System is expected to achieve improvements in biopsy accuracy which may reduce the need for radical surgery or full radiation and lower costs for the healthcare industry.


Chad Hartle


  • Hartle has been a Real Estate developer for 30 years and General Contractor for 28 years, with a primary focus in Multi-Family housing.
  • He is one of the Founders and Chairman of Alliance Bank of Cape Girardeau, Mo. and has been involved in the banking industry for over 36 years.
  • He is also a Principal in numerous insurance brokerages and is currently a member of the Board of Directors of Sunstar Insurance Group, the 45th largest Independent Insurance Agency in the United States.
  • Hartle has significant experience with new business start-ups as well as mergers and acquisitions over a wide variety of industries.

Brad J. Buscher

Chief Business Strategist

  • Mr. Buscher is a merchant banker and through his business has led the financing of the Company to date.
  • He is responsible for the Company’s current product development, product engineering, FDA clearance, IP protection strategy and establishing the Company’s reimbursement strategy.
  • Mr. Buscher has extensive experience with start-up investments in healthcare, medical diagnostics, inorganic chemistry and real estate and has been the Chairman of commercial banks, insurance brokerages, real estate development entities, leasing companies and has extensive experience in the formation and development of early stage enterprises.

Todd Anderson

Chief Financial Officer

  • Mr. Anderson has worked with Mr. Buscher for almost 20 years setting up and growing early-stage companies.
  • He brings his extensive background in setting up systems and controls for start-up entities to the initial phase of financing and operational functions of 3DBiopsy.

Dr. Nelson Stone

Chief Medical Officer and Founder

  • Dr. Stone is Professor of Urology and Radiation Oncology at the Icahn School of Medicine at Mt Sinai, NYC and has authored over 400 articles, abstracts and book chapters and recently co-authored a new book on localized prostate cancer entitled “The Prostate Cancer Dilemma: To Treat or Observe, Impact of Genetic Markers, Mapping and mpMRI.”
  • In 1995, Dr. Stone created the 3D Brachytherapy System, PROSEED which was sold to CR Bard in 1998 for $84M.
  • In 2005, Dr. Stone started Prologics, a prostate cancer radiation ablation therapy company that was successfully sold to Integrated Oncology Network in 2011 for a $10 million valuation.

Dr. E. David Crawford

Chief Scientific Officer and Founder

  • Dr. Crawford is an internationally renowned urologist, Endowed Professor of Surgery, Urology and Radiation Oncology.
  • He is Head of the Section of Urologic Oncology at the CU Denver Health Sciences Center and School of Medicine.

Dr. Marshall Lucia

Co-Founder, leads the development of the 3D pathology software

  • Dr. Lucia is Professor of Pathology and Vice Chair of Anatomic Pathology at the CU Denver Health Sciences Center and School of Medicine.
  • He has over 20 years of experience in translational biopsy research and 12 years of experience in bio-repository.
*Investigational device. Not available for sale.
Chad Hartle
Cell: 573-576-5433

Brad J. Buscher
Chief Business Strategist
Cell: 612-859-2551

Todd J. Anderson
Chief Financial Officer
Cell: 612-839-2457

Nelson N. Stone, MD
Chief MedicalOfficer and Founder
Cell: 845-323-1727

E. David Crawford, MD
Chief Scientific Officer and Founder
Cell: 303-315-5937